12 / 20
Page 37
Notes:
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 4
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
Improving patient outcome through personalized radiation immuno-oncology approaches
Mohammad K Khan
Emory University, USA
Statement of the Problem:
New immuno-oncology approaches
have emerged, to improve outcome for cancer patients.
These approaches involve the use of immune-checkpoint
inhibitors (CTLA-4, PD-1, PD-L1, etc), agonists (4-1BB, Ox 40-L),
and cytokines (IL2, IL-15), some of which have received FDA
clearance. Future direction, now involves using these agents
in combination with other approaches. One approach may
involve the use of radiotherapy. Radiotherapy has been shown
to have “immuno-genic” effects on tumor cells, T cells, APCs,
as well as the tumor micro-environment. Post radiotherapy,
abscopal effect, has been previously described, and can lead to
immune-mediated control of distant sites of disease, when one
site of tumor deposit is irradiated. The purpose of our efforts
is to improve outcome in our melanoma mouse model, and
translate these findings into ongoing clinical trials, involving
radiation and immunotherapy.
Methods:
We have developed a B16F10GPmelanoma human
syngeneic mouse model to evaluate the immunological
effects of radiation, in combination with various immune-
checkpoint modulators and cytokines (Figure 1). In addition,
our work also involves the development of tumor exosomes
as potential biomarkers of post radiation abscopal response.
Findings:
We demonstrate that several elements are needed
to maximize the optimum post radiation abscopal response,
and that the response is CD 8 T cell mediated. Considerations,
such as radiation dose, radiation fractionation, and timing
of radiation with various immune-checkpoint inhibitors are
important factors to consider when designing clinical trials.
Furthermore, tumor exosomes may play an important role
as biomarkers in abscopal response.
Conclusion & Significance:
Our data suggest that radiation
may be one strategy that could improve outcome in patients,
when combined with emerging immunotherapeutics, such
as PD-L1/PD-1, CTLA-4, 4-1BB, and others. Future clinical
trials are needed to translate this, into the clinic, as part of
multi-disciplinary approach in the future.
Speaker Biography
Mohammad K Khan has expertise as Radiation Oncologists, and as a Translational
Physician Scientist. He treats variety cancer patients, with expertise in skin cancers
and hematological malignancies. His research focuses on translating post radiation
abscopal effect into the clinic, to improve outcome for cancer patients. In particular,
he is interested in developing multi-disciplinary approaches involving radiation and
immuno-oncology to improve outcome for cancer patients. He currently leads several
efforts that span patient outcomes work, basic sciences work, as well as ongoing
clinical trials.
e:
drkhurram2000@gmail.com